Gland Pharma has announced its financial results for the second quarter ended September 30, 2026, reporting a robust 23% year-on-year increase in revenue. Profit after tax saw an even more substantial growth of 58% year-on-year, driven by strong execution across its businesses. The company highlighted growth in its CDMO business, which increased by 31%, and its Critical Injectables business, up by 18%.
Gland Pharma Announces Strong Q2 FY27 Financial Performance
Gland Pharma Limited announced its financial results for the second quarter ended September 30, 2026. The company reported a significant year-on-year revenue growth of 23%, reaching ₹18,336 million. Profit after tax (PAT) also demonstrated strong momentum, increasing by 58% year-on-year to ₹2,908 million.
Key Financial Highlights
The consolidated financial performance for Q2 FY27 showed robust improvements across key metrics:
- Revenue from operations grew by 23% year-on-year to ₹18,336 million.
- Gross Profit increased by 25% to ₹11,638 million, with the Gross Profit margin remaining stable at 63%.
- EBITDA surged by 53% to ₹4,804 million, with the EBITDA margin improving to 26% from 21% in the prior year.
- Adjusted EBITDA saw a 50% increase to ₹5,030 million, with the margin at 27%.
- Profit Before Tax (PBT) rose by 52% to ₹4,309 million.
- Profit After Tax (PAT) increased by 58% to ₹2,908 million, with the PAT margin improving to 16%.
Business Segment Performance
The company provided a breakdown of its performance by business segment:
- CDMO business revenue grew by 31% year-on-year to ₹8,227 million.
- Critical Injectables* business revenue grew by 18% year-on-year to ₹10,109 million.
Market Performance
Geographically, the company observed the following performance trends:
- USA market revenue increased by 42% to ₹11,795 million.
- Europe market revenue grew by 30% to ₹3,710 million.
- Markets such as Canada, Australia and New Zealand, and India experienced declines in revenue.
Business Highlights and Strategic Initiatives
Gland Pharma highlighted several key developments:
- R&D Expenses were ₹1,077 million in Q2 FY27, representing 6% of consolidated revenue.
- The company launched 4 molecules in the USA, including Sugammadex and Erythromycin.
- Eleven ANDAs were filed and ten were approved in the US market during the quarter.
- The Ready-to-Use (RTU) Bags portfolio addresses a market opportunity of approximately $640 million in the US.
- Two Gland Pharma facilities were audited by the USFDA, with one facility having zero observations.
The company is conducting an earnings call on November 6, 2026, at 6:30 PM IST to discuss its business performance.
Source: BSE
